MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Viatris Long-Term Debt 2011-2026 | VTRS
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Viatris
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 B | 19.7 B | 22.4 B | 11.2 B | 13.2 B | 12.9 B | 15.2 B | 6.3 B | 5.73 B | 7.59 B | 5.34 B | 4.48 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.4 B | 4.48 B | 11.8 B |
Quarterly Long-Term Debt Viatris
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.5 B | 12.8 B | 14.2 B | 14.3 B | 14.7 B | - | - | 17.2 B | 18.1 B | 18 B | 18.7 B | 19.2 B | 18.8 B | 19.7 B | 19.9 B | 20.9 B | 22.1 B | 22.4 B | 22.4 B | 22.4 B | 22.4 B | 11.2 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 22.4 B | 11.2 B | 18.1 B |
Long-Term Debt of other stocks in the Drug manufacturers industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
5.01 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
1.52 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
21.8 M | - | - | $ 754 M | USA |
 |
Alimera Sciences
ALIM
|
256 K | - | - | $ 142 M | USA |
 |
Canopy Growth Corporation
CGC
|
300 M | $ 1.14 | -4.62 % | $ 123 M |  Canada |
 |
Cronos Group
CRON
|
4.27 M | $ 2.56 | 1.24 % | $ 1.35 B | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
4.94 M | $ 4.74 | 1.94 % | $ 66.6 M | USA |
 |
Catalent
CTLT
|
4.86 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
56.2 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
8.15 B | - | - | $ 28.9 M |  Irlanda |
 |
Calliditas Therapeutics AB (publ)
CALT
|
24.1 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
29 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
5 M | - | - | $ 36.6 M | USA |
 |
DURECT Corporation
DRRX
|
16.7 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
446 M | $ 11.08 | 0.82 % | $ 567 M | USA |
 |
Athenex
ATNX
|
93 K | - | -23.39 % | $ 1.76 M | USA |
 |
Evolus
EOLS
|
122 M | $ 5.05 | -2.88 % | $ 313 M | USA |
 |
Harrow Health
HROW
|
247 M | $ 47.49 | -0.86 % | $ 1.55 B | USA |
 |
China Pharma Holdings
CPHI
|
39.9 K | $ 1.25 | - | $ 21.8 M |  China |
 |
Jupiter Wellness
JUPW
|
114 K | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.62 | 0.62 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
21.9 B | $ 6.75 | -3.3 % | $ 2.46 B | Canada |
 |
Neoleukin Therapeutics
NLTX
|
65 K | - | - | $ 193 M | Canada |
 |
Lannett Company
LCI
|
615 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
16.2 M | $ 1.58 | -2.17 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
718 K | $ 3.64 | -3.96 % | $ 479 M | USA |
 |
Pacira BioSciences
PCRX
|
585 M | $ 19.43 | 1.38 % | $ 899 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
1.12 M | $ 21.51 | 0.14 % | $ 2.05 B |  France |
 |
PetIQ
PETQ
|
438 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
3.58 B | $ 15.06 | 0.2 % | $ 2.07 B | USA |
 |
Aurora Cannabis
ACB
|
295 M | $ 4.14 | -2.13 % | $ 86.3 M | Canada |
 |
ProPhase Labs
PRPH
|
2.4 M | - | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
339 K | - | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
8.29 M | $ 1.22 | 27.44 % | $ 28.5 M | USA |
 |
Radius Health
RDUS
|
315 K | - | - | $ 1.42 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
27 K | $ 3.33 | 1.06 % | $ 4.13 M | USA |
 |
Relmada Therapeutics
RLMD
|
2.66 M | $ 3.93 | 5.01 % | $ 118 M | USA |
 |
OptiNose
OPTN
|
611 K | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
38.5 M | $ 12.04 | 4.88 % | $ 855 M | USA |
 |
Tilray
TLRY
|
221 M | $ 8.74 | -7.62 % | $ 5.4 B | Canada |
 |
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
1.23 M | $ 5.59 | 2.19 % | $ 228 M | USA |
 |
SCYNEXIS
SCYX
|
2.58 M | $ 0.65 | -0.68 % | $ 31.1 M | USA |
 |
Tricida
TCDA
|
11.3 M | - | - | $ 3.25 M | USA |
 |
Veru
VERU
|
2.92 M | $ 2.53 | -5.95 % | $ 341 M | USA |
 |
TherapeuticsMD
TXMD
|
6.53 M | $ 2.55 | 14.39 % | $ 26.6 M | USA |
 |
Zomedica Corp.
ZOM
|
1.81 M | - | -0.21 % | $ 98 M | USA |
 |
cbdMD
YCBD
|
2.4 M | $ 0.83 | -9.94 % | $ 3.58 M | USA |